Cancer Cachexia Market Expected to Reach USD 1,038 million by 2034

In 2025, the Cancer Cachexia market size across the seven major markets (7MM) was valued at USD 483 million and is expected to grow at a CAGR of 8.9%, reaching approximately USD 1,038 million by 2034. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Cancer Cachexia landscape.

DelveInsight estimates that there were roughly 1.4 million diagnosed prevalent cases of cancer cachexia across the 7MM in 2024, with the numbers projected to grow by 2034. The United States accounted for about 44% of these cases, totaling nearly 610,000 in 2024, and this figure is expected to rise throughout the 2025–2034 forecast period. Within the EU4 and the UK, Germany had the highest diagnosed prevalence at around 145,000 cases, while Spain reported the lowest at approximately 80,000. In Japan, there were about 215,000 diagnosed cases in 2024, a number also anticipated to increase by 2034.

DelveInsight’s analysis indicates a clear male predominance in cancer cachexia, with 60% of diagnosed cases in the US in 2024 occurring in men and 40% in women. Among the EU4 and the UK, colorectal cancer contributed the largest share of cancer cachexia cases at about 22%, whereas melanoma of the skin accounted for the smallest portion at roughly 2%.

In 2024, Japan recorded around 323 cancer cachexia cases in people under 20, about 9,000 cases among those aged 20–44, roughly 65,000 cases in the 45–64 age group, and nearly 140,000 cases in individuals aged 65 and above. These figures are projected to rise by 2034.

DelveInsight’s report “Cancer Cachexia Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Cancer Cachexia landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Cancer Cachexia market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Cancer Cachexia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cancer Cachexia Market Forecast

Some of the key facts of the Cancer Cachexia Market Report:

• Key Cancer Cachexia Companies: Helsinn Healthcare, Ono Pharmaceutical, Endevica Bio, Pfizer, Actimed Therapeutics, Pfizer, Aveo Oncology, Extend Biosciences, GTx, Akamis Bio, Centocor, Inc., AEterna Zentaris, Helsinn Therapeutics, Acacia Pharma, Helsinn Therapeutics, Novartis, Vicus Therapeutics, Celgene, CSL Behring, Helsinn Therapeutics, and others
• Key Cancer Cachexia Therapies: ADLUMIZ (anamorelin hydrochloride), Ponsegromab (PF-06946860), TCMCB07, ACM-001, PF 06946860, AV-380, EXT418, GTx-024, MT-102, Infliximab; Gemcitabine, Macimorelin, RC-1291, APD209, RC-1291, BYM338, VT-122, Lenalidomide, ALD518, Anamorelin HCl, and others
• The Cancer Cachexia epidemiology based on gender analyzed that through various secondary studies it can be concluded that cancer cachexia affects both males and females equally
• The Cancer Cachexia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cancer Cachexia pipeline products will significantly revolutionize the Cancer Cachexia market dynamics.

Cancer Cachexia Overview

Cancer Cachexia is a complex metabolic syndrome characterized by severe weight loss, muscle wasting, and fatigue that commonly occurs in people with advanced cancer. It results from a combination of reduced food intake and abnormal metabolism, where the body breaks down muscle and fat faster than it can be replaced. This condition cannot be fully reversed with standard nutritional support and significantly affects a patient’s strength, treatment response, and quality of life. Managing cancer cachexia involves nutritional therapy, anti-inflammatory drugs, appetite stimulants, and targeted treatments aimed at reducing muscle loss and improving overall well-being.

Get a Free sample for the Cancer Cachexia Market Report: https://www.delveinsight.com/report-store/cancer-cachexia-cc-market-insights

Key Trends in Cancer Cachexia Therapeutics Market:

• Rising Focus on Multimodal Treatment Approaches: Combination therapies involving appetite stimulants, anti-inflammatory agents, anabolic drugs, and nutritional intervention are gaining prominence over single-drug treatments to address the complex, multifactorial nature of cachexia.
• Increased R&D in Targeted & Mechanism-Based Therapies: Companies are shifting from symptomatic drugs to therapies targeting specific pathways such as IL-6, TNF-α, and GDF-15 to slow muscle wasting and improve metabolic balance.
• Growing Clinical Pipeline & Regulatory Interest: Multiple late-stage candidates, including selective androgen receptor modulators (SARMs) and ghrelin mimetics, are showing promise, attracting Fast Track and Orphan Drug designations.
• Rising Prevalence of Advanced Cancers Driving Demand: With cancer incidence and late-stage diagnosis increasing globally, the number of patients experiencing cachexia is rising, fueling market expansion.
• Emergence of Digital Health & Remote Monitoring Tools: Use of AI-based muscle mass tracking, wearable devices, and nutrition-monitoring apps is supporting more personalized management and treatment optimization.

Cancer Cachexia Epidemiology

The Cancer Cachexia epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cancer Cachexia Epidemiology Segmentation:

The Cancer Cachexia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Cancer Cachexia
• Gender-specific Cases of Cancer Cachexia
• Tumor type-specific Cases of Cancer Cachexia
• Age-specific Cases of Cancer Cachexia

Download the report to understand which factors are driving Cancer Cachexia epidemiology trends @ Cancer Cachexia Epidemiology Forecast

Cancer Cachexia Drugs Uptake and Pipeline Development Activities

The Cancer Cachexia drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cancer Cachexia market or expected to get launched during the study period. The analysis covers Cancer Cachexia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cancer Cachexia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cancer Cachexia Therapies and Key Companies

• ADLUMIZ (anamorelin hydrochloride): Helsinn Healthcare/Ono Pharmaceutical
• Ponsegromab (PF-06946860): Pfizer
• TCMCB07: Endevica Bio
• ACM-001: Actimed Therapeutics
• PF 06946860: Pfizer
• AV-380: Aveo Oncology
• EXT418: Extend Biosciences
• GTx-024: GTx
• MT-102: Akamis Bio
• Infliximab; Gemcitabine: Centocor, Inc.
• Macimorelin: AEterna Zentaris
• RC-1291: Helsinn Therapeutics
• APD209: Acacia Pharma
• RC-1291: Helsinn Therapeutics
• BYM338: Novartis
• VT-122: Vicus Therapeutics
• Lenalidomide: Celgene
• ALD518: CSL Behring
• Anamorelin HCl: Helsinn Therapeutics

Discover more about therapies set to grab major Cancer Cachexia market share @ Cancer Cachexia Treatment Market

Cancer Cachexia Market Drivers

• Increasing Global Cancer Burden: Rising incidence of advanced-stage cancers such as lung, pancreatic, gastric, and colorectal cancer is expanding the patient pool for cachexia treatment.
• Growing Awareness of Cachexia as a Distinct Clinical Condition: Shift from viewing cachexia as a secondary symptom to a treatable metabolic disorder is driving targeted therapeutic development.
• R&D Focus on Multifactorial and Combination Therapies: Surge in clinical trials exploring appetite stimulants, anti-inflammatory agents, anabolic therapies, and metabolic modulators.
• Advancements in Biomarker Research and Precision Medicine: Improved understanding of metabolic pathways, cytokines, and muscle degradation mechanisms supports personalized treatment strategies.
• Supportive Regulatory Initiatives & Orphan Drug Designations: Fast-track and orphan designations are accelerating development of novel drugs for cancer-associated cachexia.

Cancer Cachexia Market Barriers

• Lack of Approved and Effective Standard Therapies: Only a few symptomatic treatments exist, with limited efficacy and high unmet clinical need.
• Complex and Multifactorial Disease Mechanism: Involves inflammation, metabolic imbalance, and muscle wasting, making drug development challenging.
• High Failure Rate in Clinical Trials: Many investigational therapies fail due to difficulty defining endpoints, heterogeneous patient population, and late-stage diagnosis.
• Limited Awareness and Underdiagnosis in Early Stages: Cachexia is often recognized only in severe stages, reducing treatment window and clinical benefit.
• Cost and Reimbursement Challenges: Novel multimodal therapies may be expensive, and reimbursement uncertainty affects patient accessibility, especially in developing regions.

Scope of the Cancer Cachexia Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Cancer Cachexia Companies: Helsinn Healthcare, Ono Pharmaceutical, Endevica Bio, Pfizer, Actimed Therapeutics, Pfizer, Aveo Oncology, Extend Biosciences, GTx, Akamis Bio, Centocor, Inc., AEterna Zentaris, Helsinn Therapeutics, Acacia Pharma, Helsinn Therapeutics, Novartis, Vicus Therapeutics, Celgene, CSL Behring, Helsinn Therapeutics, and others
• Key Cancer Cachexia Therapies: ADLUMIZ (anamorelin hydrochloride), Ponsegromab (PF-06946860), TCMCB07, ACM-001, PF 06946860, AV-380, EXT418, GTx-024, MT-102, Infliximab; Gemcitabine, Macimorelin, RC-1291, APD209, RC-1291, BYM338, VT-122, Lenalidomide, ALD518, Anamorelin HCl, and others
• Cancer Cachexia Therapeutic Assessment: Cancer Cachexia current marketed and Cancer Cachexia emerging therapies
• Cancer Cachexia Market Dynamics: Cancer Cachexia market drivers and Cancer Cachexia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Cancer Cachexia Unmet Needs, KOL’s views, Analyst’s views, Cancer Cachexia Market Access and Reimbursement

To know more about Cancer Cachexia companies working in the treatment market, visit @ Cancer Cachexia Clinical Trials and Therapeutic Assessment